Pfizer is on the verge of claiming a multibillion-dollar first-mover advantage with their Covid-19 vaccine — analyst - Endpoints News

Pfizer is on the verge of claiming a multibillion-dollar first-mover advantage with their Covid-19 vaccine — analyst  Endpoints News